News Releases

Date Title and Summary
Toggle Summary electroCore Announces Second Quarter Financial Results
Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations Generated sequential increase in revenue Further strengthened balance sheet and reduced quarterly cash burn Company to host conference call and
Toggle Summary electroCore to Announce Second Quarter Ended June 30, 2020 Financial Results on Thursday, August 13
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2020 after the close
Toggle Summary electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients
Initial distribution to hospitals and patients expected to begin on July 31st BASKING RIDGE, N.J. , July 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced more information about availability, distribution and pricing
Toggle Summary electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia
Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache BASKING RIDGE, N.J. , July 28, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Toggle Summary Correction - electroCore Provides Business Update and Select Financial Guidance
BASKING RIDGE, N.J. , July 16, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 14, 2020 , the company’s cash was incorrectly stated as being as of the end of the first quarter. Note that the company ended the second quarter of 2020 with cash, cash equivalents and
Toggle Summary electroCore Provides Business Update and Select Financial Guidance
BASKING RIDGE, N.J. , July 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the second quarter and full year 2020.
Toggle Summary electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients
Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting BASKING RIDGE, N.J. , July 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the FDA has issued an Emergency Use Authorization (EUA)
Toggle Summary electroCore to Participate in Three Upcoming Virtual Investor Conferences
BASKING RIDGE, N.J. , July 09, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger , Chief Executive Officer, will participate in three upcoming investor conferences: Maxim Group/M-Vest COVID-19 Virtual
Toggle Summary electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference
BASKING RIDGE, N.J. , May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger , Chief Executive Officer, will be available at Little Grapevine™ (
Toggle Summary electroCore Announces First Quarter Financial Results
Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore ™ (nVNS) label expansion for migraine prevention Announced initiatives to support the potential use of nVNS for the treatment of symptoms associated with COVID-19 Company to host conference call and webcast today, May